Ideaya Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, led by CEO Yujiro S. Hata. The company is developing next-generation biomarker-enabled synthetic lethality therapies for genetically defined patient populations and an immuno-oncology pipeline targeting immuno-metabolism and innate immunity. Ideaya plans to use recent financing to advance its pipeline and aims to initiate multiple clinical studies in 2019. The company completed a significant crossover Series B financing that strengthens its balance sheet to support near-term clinical objectives. Board and observer appointments coincided with the financing, indicating investor engagement in governance and scientific oversight. Ideaya Biosciences focuses on the discovery and development of personalized synthetic lethality medicines that target DNA damage and repair, and on immuno-oncology therapies aimed at the tumor microenvironment. The company pursues small-molecule agents that exploit novel synthetic lethal interactions in genetically defined patient populations. Another strategic priority is modulating DNA repair to augment responses to immunotherapy. Drug discovery programs also target pathways known to produce an immune-suppressed tumor microenvironment to prevent tumor immune escape. Ideaya is led by co-founder and CEO Yujiro S. Hata, with senior leadership including Jeffrey Hager and Michael Dillon. The company is based in South San Francisco and La Jolla, California. Ideaya recently strengthened its balance sheet by closing a significant institutional financing to advance its discovery programs.

Total raised

$140M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2018